The pathophysiologic role of cyclo-oxygenases in the eye

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 2, 2008, Pages 141-151

  Radi, Zaher A ^a   Render, James A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUNIXIN MEGLUMINE; FLURBIPROFEN; FR 122047; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; SUPROFEN; UNCLASSIFIED DRUG;

DRUG EFFICACY; ENZYME ACTIVITY; EYE DISEASE; NONHUMAN; OPHTHALMOLOGY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; EYE DISEASES; GENE EXPRESSION; HUMANS; PROSTAGLANDINS;

EID: 41349096517     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0078     Document Type: Review

References (100)

1. Bazan, N.G., and Allan, G. Signal transduction and gene expression in the eye: A contemporary view of the proinflammatory, anti-inflammatory, and modulatory roles of prostaglandins and other bioactive lipids. Surv. Ophthalmol. 41(Suppl. 2):S23-S34, 1997.
2. Radi, Z., and Khan, N. Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp. Tox. Pathol. 58:163-173, 2006.
3. Hardy, P., Abran, D., Li, D.Y., et al. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: Interaction with prostaglandins. Invest. Ophthalmol. Vis. Sci. 35:580-5891, 1994.
4. Damm, J., Rau, T., Maihofner, C., et al. Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body. Exp. Eye Res. 72:611-621, 2001.
5. Schalnus, R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217:89-98, 2003.
6. Wilkinson-Berka, J.L. Vasoactive factors and diabetic retinopathy: Vascular endothelial growth factor, cycoloxygenase-2, and nitric oxide. Curr. Pharm. Des. 10:3331-3348, 2004.
7. Kulkarni, P.S., and Srinivasan, B.D. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. Prog. Clin. Biol. Res. 312:39-52, 1989.
8. Asakura, T., Sano, N., and Shichi, H. Prostaglandin synthesis and accumulation by porcine ciliary epithelium. J. Ocul. Pharmacol. Ther. 8:333-341, 1992.
9. Poyer, J.F., Gabelt, B., and Kaufman, P.L. The effect of topical PGF2 alpha on uveoscleral outflow and outflow facility in the rabbit eye. Exp. Eye Res. 54:277-283, 1992.
10. Kulkarni, P., and Payne, S. Eicosanoids in bovine retinal microcirculation. J. Ocul. Pharmacol. Ther. 13: 139-149, 1997.
11. Hardy, P., Bhattacharya, M., Abran, D., et al. Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-1 and -2 inhibition. Invest. Ophthalmol. Vis. Sci. 39:1888-1898, 1998.
12. Takamatsu, M., Hotehama, Y., Goh, Y., et al. Localization of prostaglandin E receptor subtypes in the ciliary body of mouse eye. Exp. Eye Res. 70:623-628, 2000.
13. Yamaji K, Yoshitomi T, Ishikawa H, et al. Prostaglandins E1 and E2, but not F2 alpha or latanoprost, inhibit monkey ciliary muscle contraction. Curr. Eye Res. 30:661-665, 2005.
14. Matsuo, T., and Cynader, M.S. Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye. Br. J. Ophthalmol. 76:210-213, 1992.
15. Zhao, C., Fujimoto, N., and Shichi, H. Immunocytochemical localization of prostaglandin E2 receptor subtypes in porcine ocular tissues. I. Uveal tissues. J. Ocul. Pharmacol. Ther. 11:421-435, 1995.
16. 2 alpha receptors on the retinal vasculature of the pig. Prostaglandins 50:253-267, 1995.
17. 2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br. J. Ophthalmol. 77:110-114, 1993.
18. Anthony, T.L., Lindsey, J.D., Aihara, M., et al. Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera. Invest. Ophthalmol. Vis. Sci. 42:3182-3186, 2001.
19. 4 prostanoid receptors in immortalized human trabecular meshwork and nonpigmented ciliary epithelial cells. J. Ocul. Pharmacol. Ther. 17:35-46, 2001.
20. Zhao, C., and Shichi, H. Immunocytochemical localization of prostaglandin E2 receptor subtypes in porcine ocular tissues. II. Nonuveal tissues. J. Ocul. Pharmacol. Ther. 11:437-445, 1995.
21. Kamphuis, W., Schneemann, A., Shichi, H., et al. Immunolocalization of prostanoid EP-receptor isotypes in human trabecular meshwork. Curr. Eye Res. 29:17-26, 2004.
22. Bito, L.Z. Species differences in the responses of the eye to irritation and trauma: A hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp. Eye Res. 39:807-829, 1984.
23. DeSantis, L.L., Jr., and Sallee, V.L. Comparison of the effects of prostaglandins and their esters on bloodaqueous barrier integrity and intraocular pressure in rabbits. Prog. Clin. Biol. Res. 312:379-386, 1989.
24. Bhattacherjee, P. Prostaglandins and inflammatory reactions in the eye. Meth. Find. Exp. Clin. Pharmacol. 2:17-31, 1980.
25. Eakins, K.E., Whitelocke, R.A., Perkins, E.S., et al. Release of prostaglandins in ocular inflammation in the rabbit. Nat. New Biol. 239:248-249, 1972.
26. 2-like activity into aqueous humor after paracentesis and its prevention by aspirin. Invest. Ophthalmol. 12:939-942, 1973.
27. Hall, D.W., and Jaitly, K.D. Inflammatory responses of the rabbit eye to prostaglandins. Agents Actions Suppl. 2:123-133, 1977.
28. 2: Effects on corneal endothelial cell migration and monolayer spreading during wound repair in vitro. Curr. Eye Res. 14:601-609, 1995.
29. 2. Invest. Ophthalmol. Vis. Sci. 35:2783-2790, 1994.
30. 2 synthesis. Invest. Ophthalmol. Vis. Sci. 37:1294-1301, 1996.
31. Camras, C.B., Alm, A., Watson, P., et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 103:1916-1924, 1996.
32. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138-147, 1996.
33. Mishima, H.K., Kiuchi, Y., Takamatsu, M., et al. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Ophthalmol. 41(Suppl. 2):S139-S144, 1997.
34. Noecker, R.S., Dirks, M.S., Choplin, N.T., et al., for the Bimatoprost/Latanoprost Study Group. A six-month randomized, clinical trial comparing the intraocular-pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:55-63, 2003.
35. Maihofner, C., Schlotzer-Schrehardt, U., Guhring, H., et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest. Ophthalmol. Vis. Sci. 42:2616-2624, 2001.
36. 2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
37. Sagara, T., Gaton, D.D., Lindsey, J.D., et al. Topical prostaglandin F2 alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117:794-801, 1999.
38. 2 alpha. Exp. Eye Res. 47:761-769, 1988.
39. Hata, Y., Clermont, A., Yamauchi, T., et al. Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J. Clin. Invest. 106: 541-550, 2000.
40. Boeri, D., Maiello, M., and Lorenzi, M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 50:1432-1439, 2001.
41. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter, randomized, controlled, clinical trial. Diabetes 38:491-498, 1989.
42. Kern, T.S., and Engerman, R.L. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 50:1636-1642, 2001.
43. Joussen, A.M., Poulaki, V., Mitsiades, N., et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 16:438-440, 2002.
44. Kulkarni, P.S., Fleisher, L., and Srinivasan, B.D. The synthesis of cyclooxygenase products in ocular tissues of various species. Curr. Eye Res. 3:447-452, 1984.
45. Amico, C., Yakimov, M., Catania, M.V., et al. Differential expression of cyclooxygenase-1 and cyclooxygenase-2 in the cornea during wound healing. Tissue Cell. 36:1-12, 2004.
46. Miyamoto, T., Saika, S., Okada, Y., et al. Expression of cyclooxygenase-2 in corneal cells after photorefractive keratectomy and laser in situ keratomileusis in rabbits. J. Cataract Refract. Surg. 30:2612-2617, 2004.
47. Ju, W.K., and Neufeld, A.H. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J. Comp. Neurol. 452:392-399, 2002.
48. Neufeld, A.H., Hernandez, M.R., Gonzalez, M., et al. Cyclooxygenase-1 and cyclooxygenase-2 in the human optic nerve head. Exp. Eye Res. 65:739-745, 1997.
49. Oka, T., Shearer, T., and Azuma, M. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr. Eye Res. 29:27-34, 2004.
50. Biswas, P.S., Banerjee, K., Kim, B., et al. Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease. J. Virol. 79: 10589-10600, 2005.
51. Sellers, R.S., Silverman, L., and Khan, K.N. Cyclooxygenase-2 expression in the cornea of dogs with keratitis. Vet. Pathol. 41:116-121, 2004.
52. Marshall, J.L., Stanfield, K.M., Silverman, L., et al. Enhanced expression of cyclooxygenase-2 in glaucomatous dog eyes. Vet. Ophthalmol. 7:59-62, 2004.
53. Masferrer, J.L., Koki, A., and Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. N. Y. Acad. Sci. 889:84-86, 1999.
54. Wilson, S.E., Netto, M., and Ambrosio, R., Jr. Corneal cells: Chatty in development, homeostasis, wound healing, and disease. Am. J. Ophthalmol. 136:530-536, 2003.
55. Bazan, H.E., Birkle, D.L., Beuerman, R.W., et al. Inflammation-induced stimulation of the synthesis of prostaglandins and lipoxygenase-reaction products in rabbit cornea. Curr. Eye Res. 4:175-179, 1985.
56. Davies, P., Bailey, P.J., Goldenberg, M.M., et al. The role of arachidonic acid oxygenation products in pain and inflammation. Ann. Rev. Immunol. 2:335-357, 1984.
57. Chang, M.S., Tsai, J.C., Yang, R., et al. Induction of rabbit cyclooxygenase-2 in the anterior uvea following glaucoma filtration surgery. Curr. Eye Res. 16:1147-1151, 1997.
58. Degi, R., Thore, C., Bari, F., et al. Ischemia increases prostaglandin H synthase-2 levels in retina and visual cortex in piglets. Graefe's Arch. Clin. Exp. Ophthalmol. 239:59-65, 2001.
59. Wilkinson-Berka, J.L., Alousis, N.S., Kelly, D.J., et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 44:974-979, 2003.
60. Ershov, A.V., and Bazan, N.G. Induction of cyclooxygenase-2 gene expression in retinal pigment epithelium cells by photoreceptor rod outer segment phagocytosis and growth factors. J. Neurosci. Res. 58:254-261, 1999.
61. Sennlaub, F., Valamanesh, F., Vazquez-Tello, A., et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108:198-204, 2003.
62. Fang, C., Jiang, Z., and Tomlinson, D.R. Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes. Effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels. Prostag. Leukot. Essent. Fatty Acids 56:157-163, 1997.
63. Yamada, M., Kawai, M., Kawai, Y., et al. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 19:300-304, 199.
64. Bonazzi, A., Mastyugin, V., Mieyal, P.A., et al. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J. Biol. Chem. 275:2837-2844, 2000.
65. 2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 498:275-278, 2004.
66. Adamis, A.P., Miller, J.W., Bernal, M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-450, 1994.
67. Adamis, A.P. Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol. 86:363-365, 2002.
68. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994.
69. Cursiefen, C., Rummelt, C., and Kuchle, M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta-1 in human corneas with neovascularization. Cornea 19:526-533, 2000.
70. Lopez, P.F., Sippy, B.D., Lambert, H.M., et al. Trans-differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37:855-868, 1996.
71. Frank, R.N. Diabetic retinopathy. N. Engl. J. Med. 350:48-58, 2004.
72. 2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest. Ophthalmol. Vis. Sci. 39:581-591, 1998.
73. Castro, M.R., Lutz, D., and Edelman, J.L. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp. Eye Res. 79:275-285, 2004.
74. Miller, J.W., Adamis, A.P., Shima, D.T., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145:574-584, 1994.
75. Koralewska-Makar, A., Johnsson, C., Bruun, A., et al. COX-2 inhibitors prolong trauma-induced elevations of iris hyaluronan. J. Ocul. Pharmacol. Ther. 19:385-395, 2003.
76. Ayalasomayajula, S.P., and Kompella, U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458:283-289, 2003.
77. Ayalasomayajula, S.P., and Kompella, U.B. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 21:1797-1804, 2004.
78. Masferrer, J.L., Leahy, K.M., Koki, A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res.60:1306-1311, 2000.
79. Takahashi, H., Yanagi, Y., Tamaki, Y., et al. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem. Biophys. Res. Commun. 325:461-466, 2004.
80. Gebhardt, B.M., Varnell, E.D., and Kaufman, H.E. Inhibition of cyclooxygenase-2 synthesis suppresses Herpes simplex virus type 1 reactivation. J. Ocul. Pharmacol. Ther. 21:114-120, 2005.
81. Coulter, D.M., and Clark, D.W. Disturbance of vision by COX-2 inhibitors. Exp. Opin. Drug Saf. 3:607-614, 2004.
82. Ju, W.K., Kim, K.Y., and Neufeld, A.H. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp. Eye Res. 77:137-145, 2003.
83. Yoshida, H., Kubota, T., and Krueger, J.M. A cyclooxygenase-2 inhibitor attenuates spontaneous and TNF-alpha-induced non-rapid eye movement sleep in rabbits. Am. J. Physiol. Reg. Integr. Comp. Physiol. 285:R99-R109, 2003.
84. 2 levels. Br. J. Ophthalmol. 68:656-659, 1984.
85. Sakamoto, T., Soriano, D., Nassaralla, J., et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol. 113:222-226, 1995.
86. Takahashi, K., Saishin, Y., Saishin, Y., et al. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 44:409-415, 2003.
87. Gaynes, B.I., and Fiscella, R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Saf. 25:233-250, 2002.
88. Giuliano, E.A. Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology. Vet. Clin. North Am. Small Anim. Pract. 34:707-723, 2004.
89. Ward, D.A. Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs. Am. J. Vet. Res. 57:875-878, 1996.
90. Millichamp, N.J., Dziezyc, J., Rohde, B.H., et al. Acute effects of anti-inflammatory drugs on neodymium: yttrium aluminum garnet laser-induced uveitis in dogs. Am. J. Vet. Res. 52:1279-1284, 1991.
91. 2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res. 36:321-326, 2004.
92. Gardiner, T.A., Anderson, H.R., Degenhardt, T., et al. Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 46:1269-1275, 2003.
93. Yamauchi, H., Iso, T., Iwao, J., et al. The role of prostaglandins in experimental ocular inflammations. Agents Actions 9:280-283, 1979.
94. van Delft, J.L., van Haeringen, N.J., Glasius, E., et al. Comparison of the effects of corticosteroids and indomethacin on the response of the blood-aqueous barrier to injury. Curr. Eye Res. 6:419-425, 1987.
95. Gersony, W.M., Peckham, G.J., Ellison, R.C., et al. Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study. J. Pediatr. 102:895-906, 1983.
96. Gupta, A.G., Hirakata, A., and Proia, A.D. Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Exp. Eye Res. 56:701-708, 1993.
97. Chemtob, S., Beharry, K., Rex, J., et al. Ibuprofen enhances retinal and choroidal blood-flow autoregulation in newborn piglets. Invest. Ophthalmol. Vis. Sci. 32:1799-1807, 1991.
98. Price, F.W. New pieces for the puzzle: Nonsteroidal anti-inflammatory drugs and corneal ulcers. J. Cataract Refract. Surg. 26:1263-1265, 2000.
99. Shimazaki, J., Saito, H., Yang, H.Y., et al. Persistent epithelial defect following penetrating keratoplasty: An adverse effect of diclofenac eyedrops. Cornea 14:623-627, 1995.
100. Shimazaki, J., Fujishima, H., Yagi, Y., et al. Effects of diclofenac eye drops on corneal epithelial structure and function after small-incision cataract surgery. Ophthalmology 103:50-57, 1996.